A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

BACKGROUND: PG545 (pixatimod) is a novel immunomodulatory agent, which has been demonstrated to stimulate innate immune responses against tumours in preclinical cancer models. METHODS: This Phase I study investigated the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Dredge, Keith, Brennan, Todd V., Hammond, Edward, Lickliter, Jason D., Lin, Liwen, Bampton, Darryn, Handley, Paul, Lankesheer, Fleur, Morrish, Glynn, Yang, Yiping, Brown, Michael P., Millward, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931096/
https://www.ncbi.nlm.nih.gov/pubmed/29531325
http://dx.doi.org/10.1038/s41416-018-0006-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931096/
https://www.ncbi.nlm.nih.gov/pubmed/29531325
http://dx.doi.org/10.1038/s41416-018-0006-0

Ejemplares similares